داء الخلايا المِنْجلية
معالجة فقر الدم
العربية
معالجة فقر الدم
/assets/ct/a63ae92c98/images/syn_placeholder_sqr.png

داء الخلايا المِنْجلية

معالجة فقر الدم

A phase 1b/2 study of the efficacy and safety of combination hydroxyurea and dose-escalated erythropoietin for treatment of anemia in sickle cell disease (ACHiEvE-SCD). (يفتح نافذة جديدة)

Adeyemo TA, Kiriza N, Oluwole FT, Jelinek M, Jonassaint J, Oluwole O, Saber C, Philips BJ, Akinsanya OJD, Osunkalu VO, DeCastro LM, Novelli EM, Xu JZ

Source‎: Blood 2024;144(Suppl 1):178-9.

مفهرسة‎: DOI

DOI‎: 10.1182/blood-2024-205261

https://ashpublications.org/blood/article/144/Supplement%201/178/530726/A-Phase-1b-2-Study-of-the-Efficacy-and-Safety-of (يفتح نافذة جديدة)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (يفتح نافذة جديدة)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Source‎: Acta Haematol 1995;94(3):128-34.

مفهرسة‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (يفتح نافذة جديدة)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (يفتح نافذة جديدة)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Source‎: Haematologica 2006;91(8):1076-83.

مفهرسة‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (يفتح نافذة جديدة)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (يفتح نافذة جديدة)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Source‎: J Obstet Gynaecol 2007;27(1):82-3.

مفهرسة‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (يفتح نافذة جديدة)